Cardiac magnetic resonance in hypertrophic cardiomyopathy: Current state of the art

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 1, 2010, Pages 103-111

  Kwon, Deborah H ^a   Desai, Milind Y ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cardiac magnetic resonance; hypertrophic cardiomyopathy; left ventricular outflow tract

Indexed keywords

GADOLINIUM;

ABLATION THERAPY; BLOOD FLOW; CARDIAC MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; GENOTYPE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART PAPILLARY MUSCLE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SCREENING TEST; TREATMENT PLANNING; ECHOCARDIOGRAPHY; GENETICS; HEART LEFT VENTRICLE FUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

CARDIOMYOPATHY, HYPERTROPHIC; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; GENOTYPE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 77949530885     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.108     Document Type: Review

References (81)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 287, 1308-1320 (2002).
2. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 30(Suppl. 4), 3-119 (1964).
3. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am. J. Cardiol. 72, 970-972 (1993).
4. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281, 650-655 (1999).
5. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N. Engl. J. Med. 320, 749-755 (1989).
6. Elliott P. Relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357, 420-424 (2001).
7. Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology/ European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J. Am. Coll. Cardiol. 42, 1687-1713 (2003).
8. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation 113, E858-E862 (2006).
9. Maron BJ, Moller JH, Seidman CE et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases:hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association]. Circulation 98, 1460-1471 (1998).
10. Richard P, Charron P, Carrier L et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107, 2227-2232 (2003).
11. Maron BJ, Olivotto I, Bellone P, Conte MR et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 39, 301-307 (2002).
12. Maron BJ. Hypertrophic cardiomyopathy. Lancet 350, 127-133 (1997).
13. Spirito P. The Management of Hypertrophic Cardiomyopathy. N. Engl. J. Med. 336, 775-785 (1997).
14. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 363, 1881-1891 (2004).
15. Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 332, 1251-1255 (2006).
16. Elliott PM, Poloniecki J, Dickie S et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J. Am. Coll. Cardiol. 36, 2212-2218 (2000).
17. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 342, 1778-1785 (2000).
18. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 42, 873-879 (2003).
19. Yoshida N, Ikeda H, Wada T et al. Exercise-induced abnormal blood pressure responses are related to subendocardial ischemia in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 32, 1938-1942 (1998).
20. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104, 2517-2524 (2001).
21. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 79, 331-336 (1998).
22. Moolman JC, Corfield VA, Posen B et al. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol. 29, 549-555 (1997).
23. Watkins H. Sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 342, 422-424 (2000).
24. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295-303 (2003). (Pubitemid 36119984)
25. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community- based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J. Am. Coll. Cardiol. 41, 987-993 (2003).
26. Kwon DH, Setser RM, Popovic ZB et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int. J. Cardiovasc. Imaging 24(6), 617-625 (2008).
27. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 51, 1369-1374 (2008).
28. Teraoka K, Hirano M, Ookubo H et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn. Reson. Imaging22, 155-161 (2004).
29. Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J. Am. Coll. Cardiol. 44, 1164-1171 (2004).
30. Simonetti OP, Kim RJ, Fieno DS et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218, 215-223 (2001).
31. Grothues F, Smith GC, Moon JC et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am. J. Cardiol. 90, 29-34 (2002).
32. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2, 271-278 (2000).
33. Pennell DJ, Sechtem UP, Higgins CB et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J. Cardiovasc. Magn. Reson. 6, 727-765 (2004).
34. Rickers C, Wilke NM, Jerosch-Herold M et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112, 855-861 (2005).
35. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 90, 645-649 (2004).
36. Olivotto I, Maron MS, Autore C et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 52, 559-566 (2008).
37. Schulz-Menger J, Abdel-Aty H, Rudolph A et al. Gender-specific differences in left ventricular remodelling and fibrosis in hypertrophic cardiomyopathy: insights from cardiovascular magnetic resonance. Eur. J. Heart Fail. 10, 850-854 (2008).
38. Maron MS, Finley JJ, Bos JM et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 118, 1541-1549 (2008).
39. Kwon DH, Smedira NG, Popovic ZB et al. Steep left ventricle to aortic root angle and hypertrophic obstructive cardiomyopathy: study of a novel association using 3-dimensional multi-modality imaging. Heart 9, 1784-1791 (2009).
40. Kwon DH, Setser RM, Thamilarasan M et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 94, 1295-1301 (2008).
41. Harrigan CJ, Appelbaum E, Maron BJ et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am. J. Cardiol. 101, 668-673 (2008).
42. O'Connor M, Wolstenholme GEW. Hypertrophic obstructive cardiomyopathy, Wolstenholme GEW, O'Connor M (Eds). Churchill, London, UK, 220 (1971).
43. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 85, 1651-1660 (1992).
44. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 87, 1570-1579 (1993).
45. Krasnow N. An acquired disease component in hypertrophic cardiomyopathy: new clinical clarifications. J. Am. Coll. Cardiol. 13, 46-47 (1989).
46. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 36, 1344-1354 (2000).
47. Henry WL, Clark CE, Griffith JM, Epstein SE. Mechanism of left ventricular outlfow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am. J. Cardiol. 35, 337-345 (1975).
48. Reis RL, Bolton MR, King JF, Pugh DM, Dunn MI, Mason DT. Anterion-superior displacement of papillary muscles producing obstruction and mitral regurgitation in idiopathic hypertrophic subaortic stenosis. Operative relief by posterior-superior realignment of papillary muscles following ventricular septal myectomy. Circulation 50, II181-8 (1974).
49. Kon MW, Grech ED, Ho SY, Bennett JG, Collins PD. Anomalous papillary muscle as a cause of left ventricular outflow tract obstruction in an adult. Ann. Thorac. Surg. 63, 232-234 (1997).
50. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 84, 1188-1197 (1991).
51. Galler M, Kronzon I, Slater J et al. Long-term follow-up after mitral valve reconstruction: incidence of postoperative left ventricular outflow obstruction. Circulation 74, I99-103 (1986).
52. Schiavone WA, Cosgrove DM, Lever HM, Stewart WJ, Salcedo EE. Long-term follow-up of patients with left ventricular outflow tract obstruction after Carpentier ring mitral valvuloplasty. Circulation 78, I60-I65 (1988).
53. Maron BJ, Epstein SE, Bonow RO, Wyngaarden MK, Wesley YE. Obstructive hypertrophic cardiomyopathy associated with minimal left ventricular hypertrophy. Am. J. Cardiol. 53, 377-379 (1984).
54. Kwon D, Setser R, Thamilarasan M et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 94(10), 1295-1301 (2007).
55. Austin BA, Kwon DH, Smedira NG, Thamilarasan M, Lever HM, Desai MY. Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy. J. Am. Soc. Echocardiogr. (2009) (In Press).
56. Bryant R 3rd, Smedira NG. Papillary muscle realignment for symptomatic left ventricular outflow tract obstruction. J. Thorac. Cardiovasc. Surg. 135, 223-224 (2008).
57. Dong SJ, MacGregor JH, Crawley AP et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three- dimensional tagged magnetic resonance imaging study. Circulation 90, 1200-1209 (1994).
58. Kramer CM, Reichek N, Ferrari VA, Theobald T, Dawson J, Axel L. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 90, 186-194 (1994).
59. Sipola P, Lauerma K, Jaaskelainen P et al. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the a-tropomyosin gene. Radiology 236, 815-824 (2005).
60. Mahrholdt H, Wagner A, Holly TA et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106, 2322-2327 (2002).
61. Kim RJ, Fieno DS, Parrish TB et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100, 1992-2002 (1999).
62. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J. Cardiovasc. Magn. Reson. 8, 479-482 (2006).
63. Kwon DH, Smedira NG, Rodriguez ER et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J. Am. Coll. Cardiol. 54, 242-249 (2009).
64. Setser RM, Bexell DG, O'Donnell TP et al. Quantitative assessment of myocardial scar in delayed enhancement magnetic resonance imaging. J. Magn. Reson. Imaging 18, 434-441 (2003).
65. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 8, 545-557 (1986).
66. Lorenzoni R, Gistri R, Cecchi F et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am. Heart J. 136, 972-981 (1998).
67. Petersen SE, Jerosch-Herold M, Hudsmith LE et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115, 2418-2425 (2007).
68. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 35, 36-44 (2000).
69. Kitamura M, Shimizu M, Ino H et al. Collagen remodeling and cardiac dysfunction in patients with hypertrophic cardiomyopathy: the significance of type III and VI collagens. Clin. Cardiol. 24, 325-329 (2001).
70. Choudhury L, Mahrholdt H, Wagner A et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 40, 2156-2164 (2002).
71. Moon JC, Mogensen J, Elliott PM et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 91, 1036-1040 (2005).
72. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 41, 1561-1567 (2003).
73. Popovic ZB, Kwon DH, Mishra M et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J. Am. Soc. Echocardiogr. 21, 1299-1305 (2008).
74. Schulz-Menger J, Abdel-Aty H et al. Left ventricular outflow tract planimetry by cardiovascular magnetic resonance differentiates obstructive from non-obstructive hypertrophic cardiomyopathy. J. Cardiovasc. Magn. Reson. 8, 741-746 (2006).
75. Chai P, Mohiaddin R. How we perform cardiovascular magnetic resonance flow assessment using phase-contrast velocity mapping. J. Cardiovasc. Magn. Reson. 7, 705-716 (2005).
76. Boonyasirinant T, Rajiah P, Setser RM et al. Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis: novel insights in vascular function from magnetic resonance imaging. J. Am. Coll. Cardiol. 54, 255-262 (2009).
77. van Dockum WG, Beek AM, ten Cate FJ et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111, 2503-2508 (2005).
78. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG. The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101, 1764-1766 (2000).
79. Valeti US, Nishimura RA, Holmes DR et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 49, 350-357 (2007).
80. Ennis DB, Epstein FH, Kellman P, Fananapazir L, McVeigh ER, Arai AE. Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging. Magn. Reson. Med. 50, 638-642 (2003).
81. Maceira AM, Joshi J, Prasad SK et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111, 186-193 (2005).